Paper-Tape Blister Trial in 90 Analyzed Ultramarathon Runners

November 12, 2026

Doctor’s Notes · Life in Motion · Evidence Review

Editorial disclosure: The featured image is an AI-created illustration of a fictional activity, training or occupational setting. It is not a patient, diagnosis, before-and-after image, institutional endorsement or Dr. Arsy #003 treatment result.

Reader question: What did this exact study measure, in whom, with which comparator and timepoint—and which conclusions would go beyond its evidence?

Study snapshot

Study element	Reported detail
Population	136 runners enrolled in 250-km, seven-day self-supported ultramarathons; 90 (66%) had complete data for analysis.
Design	Prospective randomized within-person trial across races in China, Australia, Egypt, Chile and Nepal.
Comparator	Paper tape applied to one randomly selected foot versus the runner's untreated opposite foot.
Timepoint	From prerace application through seven days; blister timing and location were recorded.
Key result	All analyzed runners developed blisters; 89% occurred by day 2 and 59% were on toes. Paper tape was not significantly protective (47 versus 35 events; 52% versus 39%; P=0.22), although 84% said they would use it again.
Funding/conflict context	Funding and author-conflict details were not reported in the accessible PubMed abstract.

What was actually measured?

All analyzed runners developed blisters; 89% occurred by day 2 and 59% were on toes. Paper tape was not significantly protective (47 versus 35 events; 52% versus 39%; P=0.22), although 84% said they would use it again.

This is a useful null result. The within-person design controls for many runner-level traits, but loss of 46 enrolled participants and a foot-level endpoint complicate simple interpretation.

The denominator defines the claim. People, visits, infections, episodes, isolates, feet and blisters are different analytic units. A percentage or rate using one unit cannot be silently rewritten as the percentage of people affected.

What the result does not prove

Only 90 of 136 enrolled runners had complete data. Tape placement, terrain, footwear and multiple blister sites may affect results, and satisfaction does not demonstrate efficacy.

Association and timing do not automatically prove individual causation. Footwear, surfaces, climate, ultraviolet exposure, hygiene, protective equipment, training load, prior conditions, referral patterns and access to care may change an estimate.

A PubMed record is a bibliographic source. PubMed indexing is not NIH endorsement of the authors’ conclusions, this interpretation or any product.

Intervention boundary: The tested antiperspirant, tape, tissue adhesive or sock system is not Dr. Arsy #003. Its outcomes cannot be transferred to a cosmetic moisturizer.

Keep the condition categories separate

Dryness, friction injury, sunburn, dermatitis, sensitization, fungal disease and bacterial infection are not interchangeable. A moisturizer may support hydration and the moisture barrier, but it does not diagnose infection, prevent ultraviolet injury, replace medical evaluation or substitute for activity-specific prevention.

Persistent spreading redness, drainage, fever, severe pain, rapidly worsening symptoms, a suspected contagious outbreak or major loss of function warrants prompt professional assessment. Clinicians may need microscopy, culture, patch testing, skin-prick testing or other targeted evaluation depending on the question.

Activity details worth documenting

What surface, footwear, sock, glove, mat, pool, boat, uniform, animal, climate or training load preceded the change?
Where did the problem begin, and did it change during rest, travel, deployment, competition or a different facility?
Were towels, clothing, footwear, razors, equipment or showers shared, and how were high-touch surfaces cleaned?
How often was skin wet, occluded, rubbed, heated, chilled or exposed to sun?
Did the problem alter sleep, pace, attendance, training, competition, work safety or duty status?

Prevention comes before cosmetic care

Prevention should match the hazard: well-fitted and broken-in equipment, task-appropriate textiles, friction management, clean personal gear, facility hygiene, prompt showering, ultraviolet protection and timely clinical assessment. No single intervention prevents every diagnosis.

Do not share personal skin products during an outbreak and do not test workplace, sport or environmental materials directly on skin. Follow occupational-health, sports-medicine, public-health and facility instructions for contagious or exposure-related conditions.

Primary research and authoritative guidance

Where Dr. Arsy #003 fits

Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003. Its findings do not show that #003 treats, cures or prevents eczema, infection, blisters, sunburn or sensitization; relieves pain or itch; neutralizes environmental exposures; is appropriate for every person; or provides pediatric or 24-hour efficacy.

Continue the evidence series

Evidence note: This educational article separates reported findings from interpretation. It is not a diagnosis, treatment recommendation or workplace, sports, military, maritime, animal-exposure or infection-control determination.

← Back to Doctor's Notes